Ongoing vacancies and acting leadership, combined with debates over vaccine policy, highlight the challenges of coordinating health agency leadership during emergencies.

If confirmed, Schwartz pledges to resign from UnitedHealth Group and other board roles, sell healthcare-related holdings, and recuse herself from matters involving former employers.

Other related appointments and vacancies persist across HHS and NIH, with nominees like Nicole Saphier for surgeon general and Chris Klomp for deputy health secretary amid ongoing transitions.

Past CDC leadership turmoil includes Susan Monarez’s brief tenure and firing amid vaccine policy disputes, with earlier shakeups occurring under the previous administration.

Schwartz previously served as deputy surgeon general during the COVID-19 pandemic and has no public record opposing vaccines, positioning her as a conventional nominee.

Committee Chairman Bill Cassidy described Schwartz as 'very impressive' after a favorable meeting, signaling cautious openness to her nomination.

Erica Schwartz, Trump’s nominee to lead the U.S. Centers for Disease Control and Prevention, will face a Senate confirmation hearing on July 15 before the Senate Committee on Health, Education, Labor and Pensions.

Leadership gaps persist across major U.S. health agencies, with several top posts vacant or recently filled and NIH institutes led by acting directors, underscoring ongoing turmoil in health agency leadership.

NIH and other top posts remain vacant or filled by acting officials, reflecting broad leadership turnover across federal health agencies.

The confirmation hearing will also address Sean Kaufman’s nomination for assistant secretary for preparedness and response, who would oversee national medical/public health preparations and the Strategic National Stockpile.

The broader context shows ongoing turnover across health agencies during Trump’s second term, complicating efforts to stabilize public health leadership.